SCHOTT Pharma (1SXP) Q4 2024 earnings summary

Executive summary

• FY 2024 targets were surpassed with strong revenue growth and high profitability, driven by high-value solutions (HVS) accounting for 55% of revenue and progress toward a midterm goal above 60%.

• Celebrated first anniversary as a public company, promoted to MDAX, and expanded global production capacities.

• Innovation pipeline delivered new products aligned with pharma megatrends, including optimized nest designs, large-volume ready-to-use cartridges, and focus on GLP-1, mRNA, ADCs, and homecare.

Financial highlights

• FY 2024 revenues reached €957 million, up 12% at constant currencies; Q4 revenues were €237 million, up 9% at constant currencies.

• FY 2024 EBITDA was €258 million, margin at 27.8% at constant currencies; Q4 EBITDA was €66 million, margin 27.9%.

• Earnings per share for FY 2024 was €0.99; proposed dividend payout of 16% of net income (€0.16 per share).

• FY 2024 CapEx totaled €145 million, mainly for HVS capacity expansion, €20 million below guidance.

• Free cash flow for FY 2024 was €79 million, supported by strong operational cash flow and improved working capital.

Outlook and guidance

• FY 2025 guidance: high single-digit organic revenue growth at constant currency, EBITDA margin targeted at ~26.9%, with growth expected to be back-end loaded.

• Midterm targets: revenue CAGR above 10%, EBITDA margin in low 30s, HVS revenue share above 60%.

• CapEx projected at €160–190 million for 2025, focused on HVS capacity expansion; dividend payout ratio targeted at 10–20%.